Arca
Skip to content
Tools
Tools

Bronchiolitis obliterans

Drug research and approvals for bronchiolitis obliterans: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 95 studies of bronchiolitis obliterans are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.

  • Recruiting worldwide: 95
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 95 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 6

Phase 2 9

Phase 1 or earlier 2

How its trials ended

95 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 19 whose ending is known, 42% met their primary endpoint, 0% missed it and 58% stopped early.

  • Completed, result not reported4446%
  • Ongoing2324%
  • Status unknown99%
  • Met its primary endpoint88%
  • Stopped: enrollment or feasibility55%
  • Stopped: other or unclear33%
  • Stopped: sponsor or business decision22%
  • Stopped: lack of efficacy11%

FDA orphan designations

Approved first, then open designations, newest first
Dec 21, 2021SirolimusTreatment of Bronchiolitis Obliterans SyndromeAI Therapeutics, Inc.Designated
Aug 7, 2018Interleukin-1 receptor antagonist (IL-1Ra,…Treatment of Bronchiolitis ObliteransOnspira Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Pharma America, Inc.Designated
Apr 10, 2017Recombinant human club cell proteinTreatment of bronchiolitis obliteransTrove Therapeutics, Inc.Designated
May 11, 2009Liposomal cyclosporineTreatment of bronchiolitis obliteransZambon S.p.A.Designated
Jun 24, 2008Liposomal cyclosporine for inhalationPrevention of bronchiolitis obliterans.Zambon S.p.A.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.